"The U.S. Food and Drug Administration today approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis
Cystic fibrosis is a genetic disease that affects about 30,000 pediatric and adult patients in the United "...
- Patient Information:
Details with Side Effects
Purulent pulmonary secretions contain very high concentrations of extracellular DNA released by degenerating leukocytes that accumulate in response to infection4. In vitro, Pulmozyme (dornase alfa) hydrolyzes the DNA in sputum of CF patients and reduces sputum viscoelasticity1.
When 2.5 mg Pulmozyme (dornase alfa) was administered by inhalation to eighteen CF patients, mean sputum concentrations of 3 μg/mL DNase were measurable within 15 minutes. Mean sputum concentrations declined to an average of 0.6 μg/mL two hours following inhalation. Inhalation of up to 10 mg TID of Pulmozyme (dornase alfa) by 4 CF patients for six consecutive days, did not result in a significant elevation of serum concentrations of DNase above normal endogenous levels5,6. After administration of up to 2.5 mg of Pulmozyme (dornase alfa) twice daily for six months to 321 CF patients, no accumulation of serum DNase was noted.
Pulmozyme (dornase alfa) , 2.5 mg by inhalation, was administered daily to 98 patients aged 3 months to ≤ 10 years, and bronchoalveolar lavage (BAL) fluid was obtained within 90 minutes of the first dose. BAL DNase concentrations were detectable in all patients but showed a broad range, from 0.007 to 1.8 μg/mL. Over an average of 14 days of exposure, serum DNase concentrations (mean ±s.d.) increased by 1.3 ±1.3 ng/mL for the 3 months to < 5 year age group and by 0.8 ±1.2 ng/mL for the 5 to ≤ 10 year age group. The relationship between BAL or serum DNase concentration and adverse experiences and clinical outcomes is unknown.
Pulmozyme (dornase alfa) has been evaluated in a randomized, placebo-controlled trial of clinically stable cystic fibrosis patients, 5 years of age and older, with baseline forced vital capacity (FVC) greater than or equal to 40% of predicted and receiving standard therapies for cystic fibrosis 7. Patients were treated with placebo (325 patients), 2.5 mg of Pulmozyme (dornase alfa) once a day (322 patients), or 2.5 mg of Pulmozyme (dornase alfa) twice a day (321 patients) for six months administered via a Hudson T Up-draft II® nebulizer with a Pulmo-Aide® compressor.
Both doses of Pulmozyme (dornase alfa) resulted in significant reductions when compared with the placebo group in the number of patients experiencing respiratory tract infections requiring use of parenteral antibiotics. Administration of Pulmozyme (dornase alfa) reduced the relative risk of developing a respiratory tract infection by 27% and 29% for the 2.5 mg daily dose and the 2.5 mg twice daily dose, respectively (see Table 1). The data suggest that the effects of Pulmozyme (dornase alfa) on respiratory tract infections in older patients ( > 21 years) may be smaller than in younger patients, and that twice daily dosing may be required in the older patients. Patients with baseline FVC > 85% may also benefit from twice a day dosing (see Table 1). The reduced risk of respiratory infection observed in Pulmozyme (dornase alfa) treated patients did not directly correlate with improvement in FEV1 during the initial two weeks of therapy.
Within 8 days of the start of treatment with Pulmozyme (dornase alfa) , mean FEV1 increased 7.9% in those treated once a day and 9.0% in those treated twice a day compared to the baseline values. The overall mean FEV1 during long-term therapy increased 5.8% from baseline at the 2.5 mg daily dose level and 5.6% from baseline at the 2.5 mg twice daily dose level. Placebo recipients did not show significant mean changes in pulmonary function testing (see Figure 1).
For patients 5 years of age or older, with baseline FVC greater than or equal to 40%, administration of Pulmozyme (dornase alfa) decreased the incidence of occurrence of first respiratory tract infection requiring parenteral antibiotics, and improved mean FEV1, regardless of age or baseline FVC.
Table 1: Incidence of First Respiratory Tract Infection Requiring
Parenteral Antibiotics in Patients with FVC ≥ 40% of Predicted
|2.5 mg QD
|2.5 mg BID
|Percent of Patients Infected Relative Risk (vs placebo)||43%||34% 0.73||33% 0.71|
|p-value (vs placebo)||0.015||0.007|
|Subgroup by Age and Baseline FVC||Placebo
|2.5 mg QD
|2.5 mg BID
|5-20 years||42% (201)||25% (199)||28% (184)|
|21 years and older||44% (124)||48% (123)||39% (137)|
|40-85% Predicted||54% (194)||41% (201)||44% (203)|
|> 85% Predicted||27% (131)||21% (121)||14% (118)|
Figure 1:Mean Percent Change from Baseline FEV1
in Patients with FVC ≥ 40% of Predicted
Pulmozyme (dornase alfa) has also been evaluated in a second randomized, placebo-controlled study in clinically stable patients with baseline FVC < 40% of predicted8. Patients were enrolled and treated with placebo (162 patients) or Pulmozyme (dornase alfa) 2.5 mg QD (158 patients) for 12 weeks. In patients who received Pulmozyme (dornase alfa) , there was an increase in mean change (as percent of baseline) compared to placebo in FEV1 (9.4% vs. 2.1%, p < 0.001) and in FVC (12.4% vs. 7.3% p < 0.01). Pulmozyme (dornase alfa) did not significantly reduce the risk of developing a respiratory tract infection requiring parenteral antibiotics (54% of Pulmozyme (dornase alfa) patients vs. 55% of placebo patients had experienced a respiratory tract infection by 12 weeks, relative risk = .93, p=0.62).
Clinical trials have indicated that Pulmozyme (dornase alfa) therapy can be continued or initiated during an acute respiratory exacerbation.
Short-term dose ranging studies demonstrated that doses in excess of 2.5 mg BID did not provide further improvement in FEV1. Patients who have received drug on a cyclical regimen (i.e., administration of Pulmozyme (dornase alfa) 10 mg BID for 14 days, followed by a 14 day wash out period) showed rapid improvement in FEV1 with the initiation of each cycle and a return to baseline with each Pulmozyme (dornase alfa) withdrawal.
1. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990; 87: 9188-92.
2. Boat TF. Cystic Fibrosis. In: Murray JF, Nadel JA, editors. Textbook of respiratory medicine. Philadelphia: Saunders WB, 1988; 1: 1126-52.
3. Collins FS. Cystic Fibrosis: molecular biology and therapeutic implications. Science 1992; 256: 774-9.
4. Potter JL, Spector S, Matthews LW, Lemm J. Studies of pulmonary secretions. Am Rev Respir Dis 1969; 99: 909-15.
5. Hubbard RC, McElvaney NG, Birrer P, Shak S, Robinson WW, Jolley C, et al. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Eng J Med 1992; 326: 812-5.
6. Aitken ML, Burke W, McDonald G, Shak S, Montgomery AB, Smith A. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. JAMA 1992; 267(14): 1947-51.
7. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994; 331: 637-42.
8. McCoy K, Hamilton S, Johnson C. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Chest 1996; 110: 889-95.
Last reviewed on RxList: 12/16/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Pulmozyme Information
Pulmozyme - User Reviews
Pulmozyme User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.